| abstract |
The invention relates to novel trifluoro-methyl-oxadiazole derivatives of the formula (I), and pharmaceutically acceptable salts thereof: (see formula) wherein all the variables are as defined in the specification, to pharmaceutical compositions thereof, to the pharmaceutical combinations thereof, and their use as medicaments, in particular for the treatment of neuro-degeneration, muscular atrophy or diabetes / metabolic syndrome, by means of HDAC4 inhibition. |